Fluorouracil is a drug used to treat symptoms of cancer of the colon, breast, stomach, and pancreas. It is also used in a cream to treat certain skin conditions. Fluorouracil stops cells from making DNA and it may kill cancer cells. It is a type of antimetabolite. Also called 5-fluorouracil and 5-FU.
Basal cell carcinoma is one of the most common cancers and its incidence is increasing worldwide, putting a significant burden on health services. Topical treatments are available for superficial basal cell carcinoma (BCC) but there has a lack of long-term follow-up data to guide treatment decisions.
Doctors at UCLA, Cleveland Clinic, University of California San Diego School of Medicine and additional institutions have achieved a milestone in the development of a treatment for people with recurrent glioblastoma, the most common and aggressive form of brain cancer, by successfully demonstrating a modified virus that can extend the lives of patients with the disease.
St. Jude Children's Research Hospital scientists have used sophisticated pharmacologic modeling and simulation to translate preclinical findings into a successful phase I clinical trial of a chemotherapy agent for treatment of ependymoma. The research marked the first time the approach has been used to calculate drug doses for a clinical trial in pediatric brain tumor patients.
Advances in personalized medicine allow doctors to select the most promising drugs for certain types of malignant tumors.
A post hoc analysis of the PETACC-8 trial has revealed an interaction between microsatellite instability and BRAF and KRAS mutation status when determining the prognosis of patients with resected stage III colon adenocarcinoma.
Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).
A study led by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has demonstrated the efficiency of a small molecule drug, PRIMA-1met, in inhibiting the growth of colorectal cancer cells. Colorectal cancer is the cancer of the large intestine (colon and rectum) and is the most common cancer in Singapore.
The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.
Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III DBCG77B clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.
Today, The U.S. Food and Drug Administration approved a novel therapy for patients with metastatic pancreatic adenocarcinoma – the most common form of pancreatic cancer – whose disease has progressed following gemcitabine-based therapy, offering new hope against a disease that will claim the lives of more than 40,000 individuals this year.
The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.
Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company's lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma.
Silver is often used as a coating on medical equipment used for chemotherapy. The problem is that this silver coating can break down drugs. Now, researchers have found a graphene coating that will help boost chemotherapy's effects.
A team of researchers from the Massachusetts General Hospital Center for Engineering in Medicine has developed a novel approach that dramatically simplifies the evaluation of the liver's drug-metabolizing activity and the potential toxic effects of the products of that activity on other organs.
Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.
Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University of California, San Diego School of Medicine conducted a proof-of-principle study with a small group of metastatic colorectal cancer patients.
A team of researchers from the Massachusetts General Hospital Center for Engineering in Medicine (MGH-CEM) has developed a novel approach that dramatically simplifies the evaluation of the liver's drug-metabolizing activity and the potential toxic effects of the products of that activity on other organs.
A new study published in IOP Publishing's journal 2D Materials has proposed using graphene as an alternative coating for catheters to improve the delivery of chemotherapy drugs.
Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the results of a study identifying the clinical benefit of targeted therapy in colorectal cancer (CRC) with high microsatellite instability (MSI-H), a predisposition that occurs in 15% of all CRCs causing significantly different prognosis and response to treatment.
PharmaEngine, Inc. today announced that a New Drug Application (NDA) has been submitted to the Taiwan Food and Drug Administration (TFDA) for MM-398 (irinotecan liposome injection, also known as nal-IRI) in patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.